UCBJY News and Press, UCB S.A. ADR From 02/04/22

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results - Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis - The results show...

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study - The BE COMPLETE study evaluated bimekizumab in adults with active psoriatic arthritis who were inadequate responders or intolerant to anti-TNF treatment - BE COMPLETE is the second positi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zogenix (NASDAQ: ZGNX ) stock is skyrocketing on Wednesday following news that UCB (OTCMKTS: UCBJY ) intends to acquire the company in a $1.9 billion deal. Source: Shutterstock.com The deal between the t...

UCB to acquire Zogenix - Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare dise...

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study - The BE MOBILE 1 study met the primary and all ranked secondary endpoints, showing that bimekizumab improved outcomes in patients with active non-radiographic axial spondyloarthr...

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial - BE MOBILE 2 is a Phase 3 study evaluating the efficacy and safety of bimekizumab in the treatment of patients with active ankylosing spondylitis - The trial met the primary endpoint and all r...

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care - 17 scientific presentations illustrate and reinforce UCB's commitment to improving the lives of people living with e...

UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease -- UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in...

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms -- The BE OPTIMAL study met the primary endpoint and all ranked secondary endpoints with statistical significance -- The study used t...

UCB Showcases Key Rheumatology Data at ACR Convergence 2021 -- Eleven abstracts across UCB's rheumatology portfolio, including investigational bimekizumab and CIMZIA® (certolizumab pegol), underscore UCB's dedication to rheumatology -- Long-term three-year data from Pha...